August 27, 2024

Dear CLN2 Batten Community,

We are writing to share an important and exciting update on REGENXBIO's investigational gene therapies, RGX-381 and RGX-181, for the treatment of ocular and CNS manifestations, respectively, in CLN2, a form of Batten disease.

Last November, we communicated that due to our decision to not move forward with the development of RGX-381 and RGX-181, we would pursue strategic alternatives to advance these investigational gene therapies.

We are pleased to announce that Tern Therapeutics, a private biotechnology company, acquired both RGX-381 and RGX-181 programs from REGENXBIO through a global licensing agreement. The leadership team at Tern is very familiar with both of these programs and knows the Batten community.

For more information on this news and to learn more about Tern Therapeutics, please visit their website, www.TERNTX.com.

Children currently enrolled in the RGX-381 ocular trial in the U.K. will not be impacted by the transition. Families of trial participants will be contacted and will receive further information from Drs. Paul Gissen and Rob Henderson at Great Ormond Street Hospital (GOSH) and can reach out to the study team at GOSH for more information.

Families are encouraged to contact Tern Therapeutics for information. Should you wish to contact REGENXBIO, please contact the Patient Advocacy team at CLN2@regenxbio.com.

It has been an honor to have been a part of your community. Thank you for the amazing work you all do to advocate for change for patients. We remain hopeful in the potential of RGX-381 and RGX-181, and are excited to see the progress Tern will make to help CLN2 patients.

We wish you all continued health and happiness.

Warm regards from the team at REGENXBIO,

Paulo Falabella, MD, PhD
Vice President, Clinical Development and Operations

Vivian Fernandez
Executive Director, Patient Advocacy